Cancer remains one of the most pressing global health challenges, with millions of new diagnoses each year. While precision medicine and targeted therapies have transformed treatment strategies, many patients still face drug resistance and disease recurrence. A new review published in Genes & Diseases highlights the critical role of patient-derived xenograft (PDX) models, offering a powerful preclinical platform that more accurately mimics human tumors. These models could revolutionize drug development, improve treatment efficacy, and guide personalized therapies.

Breast cancer remains the most prevalent malignancy among women worldwide, posing a critical challenge to global health. Amid the complexities of this disease, an emerging focus on metabolic reprogramming has shed light on novel treatment avenues. A newly published review delves into the intricate alterations in glucose, lipid, and amino acid metabolism that drive breast cancer progression and explores promising therapeutic strategies designed to exploit these metabolic dependencies.

Dr. Stephen Ross, co-director of NYU's Center for Psychedelic Medicine, has helped resurrect psychedelic research in psychiatry through landmark clinical trials showing that psilocybin-assisted psychotherapy produces rapid, substantial, and sustained improvements in conditions previously resistant to conventional treatments.